Skip to main content

ACC: Empagliflozin Cuts Heart Failure Hospitalization Risk After AMI

Medically reviewed by Carmen Pope, BPharm. Last updated on April 8, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, April 8, 2024 -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.

Adrian Hernandez, M.D., from Duke University in Durham, North Carolina, and colleagues examined the impact of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction in a double-blind, randomized trial. The study included 6,522 patients hospitalized for acute myocardial infarction at risk for heart failure based on newly developed left ventricular ejection fraction of <45 percent and/or signs or symptoms of congestion.

The researchers found that the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin group versus the placebo group during a median follow-up of 17.9 months (hazard ratio, 0.77 for first heart failure hospitalization; rate ratio, 0.67 for total heart failure hospitalizations). For first and total heart failure hospitalizations, the benefit of empagliflozin was consistent across clinically relevant patient subgroups. Patients randomly assigned to empagliflozin had less postdischarge need for new use of diuretics, renin-angiotensin modulators, and mineralocorticoid receptor antagonists.

"These data suggest the potential role for empagliflozin in high-risk post-myocardial infarction patients in preventing heart failure hospitalizations," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF

WEDNESDAY, Oct. 16, 2024 -- For individuals with heart failure with reduced ejection fraction (HFrEF), substantial mortality benefits would result from optimal use of...

About 6.7 Million Americans Older Than 20 Years Have Heart Failure

WEDNESDAY, Oct. 2, 2024 -- About 6.7 million Americans older than age 20 years have heart failure, according to an updated report from the Heart Failure Society of America...

Study Looks at Efficacy of Hemoglobin Thresholds for Transfusion

TUESDAY, Oct. 1, 2024 -- For patients with acute myocardial infarction (MI) and anemia, 30-day risks for death or recurrent MI seem to increase with lower hemoglobin thresholds...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.